Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago. The drugmaker said Wednesday that ...
There has been considerable controversy surrounding Aduhelm since the Food and Drug Administration (FDA) granted the drug accelerated approval in 2021. The accelerated approval of Aduhelm has been ...
(RTTNews) - Biogen Inc. (BIIB) said new data showed that after nearly two and a half years of treatment (128 weeks) with ADUHELM injection 100 mg/mL for intravenous use, patients in the long-term ...
Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history ...
HOUSTON, Texas (KTRK) -- There's a possible breakthrough in the fight against Alzheimer's. A recently-approved infusion therapy, called Aduhelm, is being used to treat the disease and a Houston man is ...
The treatment, which is administered as a monthly intravenous infusion, binds to aggregated β-amyloid and promotes removal of amyloid from the brain. The Food and Drug Administration (FDA) has ...
After the FDA approved a controversial new Alzheimer’s drug, doctors have been fielding lots of questions about it from patients and their caregivers. The drug, called Aduhelm and made by Biogen, ...
Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago. The drugmaker said Wednesday that ...
WHEN A LONG-AWAITED drug for Alzheimer’s was approved by the Food and Drug Administration (FDA) last month, controversy quickly followed. In November ten of 11 members of an FDA expert panel rejected ...
A Des Moines man has dedicated his life to advocating for the early diagnosis of Alzheimer's. Now, he's one of the first in the nation to receive a new promising treatment for the disease. Mike ...
March 14 (Reuters) - Japan's Eisai Co Ltd will surrender its rights to share profit from Aduhelm, the Alzheimer's treatment drug jointly developed with U.S. partner Biogen Inc (BIIB.O), opens new tab, ...
Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago. The drugmaker also said Wednesday that it will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback